Browsing Category
Pharma Industry News
4728 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Orphan drug designation for CTD402 raises stakes for allogeneic CAR-T in relapsed T-cell leukemia
CTD402 secures FDA orphan designation. Read how this raises execution stakes for allogeneic CAR-T in relapsed T-cell leukemia.
Lundbeck’s Vyepti shows real-world migraine relief in patients failed by prior CGRP treatments
New INFUSE study data shows Vyepti may improve outcomes in migraine patients unresponsive to CGRP therapies. Find out what this means for the market.
Stargardt disease pipeline shifts as Belite Bio clears enrollment risk for tinlarebant
Discover why Belite Bio’s DRAGON II enrollment milestone shifts Stargardt disease drug development and what it means for investors and regulators.
Why pinguecula drug development is gaining momentum after Cloudbreak Pharma’s FDA discussions
Find out why Cloudbreak Pharma’s FDA discussions are changing how investors and regulators view pinguecula drug development and late-stage ophthalmology risk.
What the end of the Kowa partnership signals for Arcutis Biotherapeutics’ commercial control of ZORYVE
Arcutis Biotherapeutics ends its Kowa partnership and takes full control of ZORYVE promotion. Find out what this signals for adoption and strategy.
Advanced melanoma immunotherapy enters a new phase as Scancell secures Phase 3 clearance
Scancell Holdings Plc, iSCIB1+, advanced melanoma, melanoma immunotherapy, FDA Phase 3 clearance, cancer vaccines, ImmunoBody platform
Why addiction treatment companies like Indivior are re-anchoring corporate control in the U.S.
Find out why Indivior’s U.S. redomiciliation signals a broader strategic shift across addiction treatment and regulated healthcare companies.
Neuropathic corneal pain drug urcosimod receives FDA compassionate use authorization
FDA authorizes compassionate use of urcosimod for neuropathic corneal pain. Discover what this changes for OKYO Pharma Limited and ophthalmology drug development.
Five-year data boosts Moderna and Merck’s neoantigen vaccine strategy in adjuvant melanoma
Moderna and Merck reveal 5-year data showing 49% reduction in melanoma recurrence with their mRNA-4157 and KEYTRUDA combo. Read more on what’s next.
J&J’s CAPLYTA nearly doubles remission rates in Phase 3 MDD trial
Find out how Johnson & Johnson’s CAPLYTA is redefining remission in depression with six-month data that could reshape MDD treatment benchmarks.